question text |
To ask Her Majesty’s Government what evidence existed to show that the Health Protection
Agency’s Lyme Borreliosis Unit (LBU) conformed with European Union and United Kingdom
legislation for the use of the Trinity Biotech kit for <i>in vitro</i> testing when
used with cerebrospinal fluid; and what testing was carried out by the LBU to verify
that the use of that test kit was suitable, and sufficiently sensitive, for the detection
of European and United Kingdom species of Borrelia infections in cerebrospinal fluid.
|
|